Efficacy of albaconazole against Candida albicans in a vaginitis model

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4540-4541

  González, Gloria M ^a   Robledo, Efrén ^a   Garza González, Elvira ^a   Elizondo, Mariana ^a   González, J Gerardo ^a  

^a Medicina UANL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALBACONAZOLE; ESTRADIOL VALERATE; FLUCONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROL GROUP; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; EXPERIMENTAL MODEL; FUNGAL STRAIN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; VAGINA CANDIDIASIS; VAGINITIS;

EID: 70349318560     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00565-09     Document Type: Article

References (15)

1. Calderon, L., R. Williams, M. Martinez, K. V. Clemons, and D. A. Stevens. 2003. Genetic susceptibility to vaginal candidiasis. Med. Mycol. 41:143-147.
2. Capilla, J., M. Ortoneda, F. J. Pastor, and J. Guarro. 2001. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob. Agents Chemother. 45:2635-2637.
3. Fernández-Torres, B., A. J. Carrillo, E. Martín, A. del Palacio, M. K. Moore, A. Valverde, M. Serrano, and J. Guarro. 2001. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob. Agents Chemother. 45:2524-2528.
4. Garau, M., M. Pereiro, and A. del Palacio. 2003. In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds. Antimicrob. Agents Chemother. 47:2342-2344.
5. González, G. M., E. Robledo, D. Saldívar, G. González, F. Bosques, and E. Garza. 2007. Therapeutic efficacy of posaconazole against isolates of Candida albicans with different susceptibilities to fluconazole in a vaginal model. Med. Mycol. 45:221-224.
6. Miller, J. L., W. A. Schell, E. A. Wills, D. L. Toffaletti, M. Boyce, D. K. Bejamin, J. Bartroli, and J. R. Perfect. 2004. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob. Agents Chemother. 48:384-387.
7. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2, 2nd ed. National Committee for Clinical Laboratory Standards, Wayne, PA.
8. Nurbhai, M., J. Grimshaw, M. Watson, C. Bond, J. Mollison, and A. Ludbrook. 2007. Oral versus intravaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst. Rev. 4:CD002845. (Pubitemid 351805327)
9. Ramos, G., M. Cuenca-Estrella, A. Monzón, and J. L. Rodríguez-Tudela. 1999. In vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J. Antimicrob. Chemother. 44:283-286. (Pubitemid 29389293)
10. Ryley, J. F., and S. McGregor. 1986. Quantification of vaginal Candida albicans infections in rodents. J. Med. Vet. Mycol. 24:455-460.
11. Slavin, M. B., G. I. Benrubi, R. Parker, C. R. Griffin, and M. J. Magee. 1992. Single dose oral fluconazole vs intravaginal terconazole in treatment of Candida vaginitis. Comparison and pilot study. J. Fla. Med. Assoc. 79:693-696.
12. Sobel, J. D. 1993. Genital candidiasis, p. 225-245. In G. P. Bodey (ed.), Candidiasis: pathogenesis, diagnosis and treatment. Raven Press Ltd., New York, NY.
13. Sobel, J. D. 2007. Vulvovaginal candidosis. Lancet 369:1961-1971.
14. Tooley, P. J. 1990. Treatment of vaginal candidosis - a UK patient survey. 1989. Br. J. Clin. Pract. 71(Suppl.):S73-S76.
15. Urbina, J. A., R. Lira, G. Visbal, and J. Bartroli. 2000. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 44:2498-2502.